摘要
缺血性心肌病是我国致死率最高的疾病,且随着人民生活水平的改善其的发病率仍在不断攀升[1]。以经皮冠状动脉介入治疗(percutaneous coro‐nary intervention,PCI)和冠状动脉旁路移植术为代表的血运重建策略是挽救缺血性心肌病患者生命、改善患者远期生存质量的有效手段,特别是随着技术的进步和设备的革新,PCI手术的适用范围不断扩大,已经成为最主要的血运重建手段.
Currently,revascularization is an effective rescue strategy for patients with acute myocardial infarction.However,myocardial ischemia/reperfusion(I/R)injury induced by revascularization has become a significant risk factor affecting the long-term prognosis of patients with ischemic cardiomyopathy after revascularization,without precise treatment.Extracellular vehicles derived from mesenchymal stem cells are characterized by easy access,editability,and easy absorption of cells,and their application in treating myocardial I/R injury is considered valuable to study.This review focuses on the advances in research on mesenchymal stem cell-derived extracellular vehicles and their function of regulating myocardial I/R injury after natural drug intervention,hopefully offering ideas for the research of prevention and treatment of myocardial I/R injury.
作者
谭景锐
江永鑫
王诗源
TAN Jingrui;JIANG Yongxin;WANG Shiyuan(Shandong University of Traditional Chinese Medicine,Jinan 250000,China;Jianggao Town Health Center,Guangzhou 510450,China)
出处
《中国病理生理杂志》
CAS
CSCD
北大核心
2024年第1期187-192,共6页
Chinese Journal of Pathophysiology
基金
山东省自然科学基金资助项目(No.ZR2020MH352)。
关键词
心肌缺血
再灌注损伤
间充质干细胞
细胞外囊泡
myocardial ischemia
reperfusion injury
mesenchymal stem cells
extracellular vehicles
